ClinicalMind Acquires 11TEN Innovation Partners, Uniting Cutting-Edge Medical Communications with Strategic Consulting to Drive Innovation in Life Sciences

NEW YORK, April 23, 2024 /PRNewswire-PRWeb/ — ClinicalMind, LLC (CM), a premier healthcare marketing and communications company, today announced the acquisition of 11TEN Innovation Partners (11TEN), a leading strategy consulting firm with a robust healthcare innovation ecosystem. This strategic move combines CM’s expertise in medical communications and training with 11TEN’s capabilities in commercial strategy and innovation consulting, offering an unparalleled end-to-end service for healthcare and life science companies.

“We are extremely excited to be bringing 11TEN into the CM family,” said Jeanne Martel, CEO of CM. “Their teams of talented, experienced strategists and visionaries are helping accelerate healthcare innovation in novel and structured ways. CM, in turn, can align our strategic communications, instructional design, and technology expertise to the strategies that 11TEN develops, providing clients with a seamless, integrated experience. I look forward to working with James and the entire 11TEN team as we move forward.”

Keep Reading: https://www.prweb.com/releases/clinicalmind-acquires-11ten-innovation-partners-uniting-cutting-edge-medical-communications-with-strategic-consulting-to-drive-innovation-in-life-sciences-302124477.html

March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
March 13, 2026
A skilled workforce is the engine that will drive growth across America’s biotechnology industry, and Atlanta has built multi-faceted training programs that are developing and sustaining the talent pipeline for everything from advanced laboratory research to industrial biomanufacturing.
March 12, 2026
On March 12, 2026, Augusta, Georgia served as the setting for an important conversation about the future of American biotechnology and manufacturing. Manus welcomed members of the U.S. National Security Commission on Emerging Biotechnology (NSCEB) to its Augusta BioFacility to highlight how advanced biomanufacturing is strengthening U.S. supply chain resilience and supporting the growing bioeconomy. During the visit, Manus unveiled a significant expansion of its 44-acre Augusta BioFacility, increasing domestic capacity to produce critical biobased ingredients. The expansion further positions Georgia as a key hub for advanced biomanufacturing and demonstrates the growing role of biotechnology in strengthening national economic and supply chain security. Commission members met with leaders from industry, government, and academia to discuss strategies for scaling manufacturing infrastructure, strengthening resilient supply chains, and preparing the workforce needed to support the next generation of the U.S. bioeconomy. The visit also included conversations with Manus employees about the practical realities of building and operating advanced biomanufacturing facilities in the United States. The Augusta site has become one of the largest advanced biomanufacturing facilities in the country, producing a growing portfolio of bioalternatives at industrial scale. Among these products is high-purity Reb M, recently launched as Yume™ M Stevia Sweetener , supported by an all-Americas supply chain. “As we scale the Manus bioalternatives platform, Augusta has become a powerful example of what the modern U.S. bioeconomy looks like in practice,” said Manus Founder and CEO Ajikumar Parayil. The visit underscores Georgia’s expanding leadership in life sciences manufacturing and highlights how regional ecosystems can help advance U.S. leadership in biotechnology and biomanufacturing. Learn more about the expansion and visit: Manus welcomes U.S. National Security Commission on Emerging Biotechnology to unveil major Augusta BioFacility expansion Growing Georgia Biomanufacturing Industry Transforming American Industrial Strength
MORE POSTS